B
KROS icon

Braidwell’s Keros Therapeutics KROS Stock Holding History

Braidwell’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,894,439
Closed -$30M – 74
2024
Q4 		$30M Buy
1,894,439
+1,187,199
+168% +$61.7M 0.89% 42
2024
Q3 		$41.1M Sell
707,240
-274,969
-28% -$13.6M 1.16% 36
2024
Q2 		$44.9M Buy
982,209
+244,830
+33% +$13.2M 1.41% 30
2024
Q1 		$48.8M Sell
737,379
-381,582
-34% -$22.6M 1.57% 27
2023
Q4 		$44.5M Sell
1,118,961
-238,348
-18% -$7.47M 1.63% 22
2023
Q3 		$43.3M Buy
1,357,309
+213,444
+19% +$7.97M 1.37% 25
2023
Q2 		$46M Buy
+1,143,865
New +$50.1M 1.5% 21

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Braidwell's KROS Position: Q1 2025 in Review

Braidwell sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 1,894,439 shares — an estimated $30M sold.

Braidwell first reported a position in KROS in Q2 2023 and held it in 7 quarters. The position peaked at $48.8M in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Braidwell reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Braidwell sold 1,894,439 Keros Therapeutics shares in Q1 2025, an estimated $30M.
  • Braidwell first reported a position in Keros Therapeutics in Q2 2023 and held it in 7 quarters.
  • Braidwell's Keros Therapeutics position peaked at $48.8M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.